Uncategorized

April 30, 2020

Integral Molecular Develops Test for Neutralizing Antibodies in COVID-19 Patients and Clinical Trials

PHILADELPHIA – Integral Molecular announces the launch of SARS-CoV-2 Reporter Virus Particles (RVPs) to test patients for the presence of neutralizing antibodies, determine the effectiveness of […]
April 21, 2020

Integral Molecular Receives NIAID Award to Combat COVID-19

PHILADELPHIA – The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to enable the application of Integral Molecular’s technology platforms […]
March 9, 2020

Integral Molecular Accelerates Coronavirus Vaccine Research

PHILADELPHIA –Integral Molecular announces the mobilization of two of its key technology platforms to aid in the discovery of vaccines and therapeutics against the novel coronavirus […]
February 12, 2020

Integral Molecular Launches ReadyMap Services for Rapid, Conformational Epitope Mapping

PHILADELPHIA –Integral Molecular, the industry leader in the discovery and characterization of antibodies against membrane proteins, announces the launch of ReadyMap services, an expansion of its […]
January 8, 2020

Integral Molecular Announces Preclinical P2X7 Antibody Assets for Autoimmune Disorders

PHILADELPHIA – Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces lead monoclonal antibodies (MAbs) against P2X7, a structurally complex ion channel that […]
November 14, 2019

Integral Molecular to Advance Vaccine Discovery with NIH Contract for $5.5M

PHILADELPHIA – (PR NEWSWIRE) – The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular a contract (75N93019C00073) which will provide up to […]